Clinical Trials Directory

Trials / Completed

CompletedNCT00261079

Fexofenadine in Pruritic Skin Disease

The Evaluation of Efficacy and Safety of Fexofenadine 180mg Tablets for 7 Days in the Treatment of Pruritic Skin Disease

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
435 (actual)
Sponsor
Handok Inc. · Industry
Sex
All
Age
12 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Primary objective: * To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin disease Secondary objective: * To evaluate patient's satisfaction of Allegra treatment

Conditions

Interventions

TypeNameDescription
DRUGFexofenadine

Timeline

Start date
2005-04-01
Completion
2006-10-01
First posted
2005-12-02
Last updated
2007-11-07

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT00261079. Inclusion in this directory is not an endorsement.

Fexofenadine in Pruritic Skin Disease (NCT00261079) · Clinical Trials Directory